The immunogenicity of virus-derived 2A sequences in immunocompetent individuals

Gene Therapy

Volumn 20, Issue 9, 2013, Pages 958-962

  Arber, C ^a   Abhyankar, H ^a   Heslop, H E ^a   Brenner, M K ^a   Liu, H ^a   Dotti, G ^a   Savoldo, B ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

2A sequences; Immunogenicity; Polycistronic vectors; T cell gene transfer

Indexed keywords

GAMMA INTERFERON; IONOMYCIN; RETROVIRUS VECTOR;

2A EQUINE RHINITIS VIRUS; 2A THOSEA ASIGNA VIRUS; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DONOR; EX VIVO STUDY; FLOW CYTOMETRY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; PRIORITY JOURNAL; T LYMPHOCYTE; VIRAL GENE THERAPY; VIRUS;

EQUIDAE; EQUINE RHINITIS A VIRUS; THOSEA ASIGNA VIRUS; TOMATO ASPERMY VIRUS;

AMINO ACID SEQUENCE; ANTIGENS; APHTHOVIRUS; CELL LINE; GENETIC VECTORS; HEALTHY VOLUNTEERS; HUMANS; IMMUNOCOMPETENCE; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDES; RNA VIRUSES; T-LYMPHOCYTES;

EID: 84883861213     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.25     Document Type: Article

References (21)

1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12: 269-281.
2. Hoyos V, Savoldo B, Dotti G. Genetic modification of human T lymphocytes for the treatment of hematological malignancies. Haematologica 2012; 97: 1622-1631.
3. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012; 72: 3125-3130.
4. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010; 33: 780-788.
5. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113: 6392-6402.
6. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110: 2793-2802. (Pubitemid 350006931)
7. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24: 1160-1170.
8. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 2011; 19: 751-759.
9. Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest 2012; 122: 2221-2233.
10. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-1464.
11. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822-1826.
12. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
13. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365: 1673-1683.
14. Szymczak-Workman AL, Vignali KM, Vignali DA. Design and construction of 2A peptide-linked multicistronic vectors. Cold Spring Harb Protoc 2012; 2012: 199-204.
15. de Felipe P. Skipping the co-expression problem: the new 2A 'CHYSEL' technology. Genet Vaccines Ther 2004; 2: 13.
16. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptidebased retroviral vector. Nat Biotechnol 2004; 22: 589-594. (Pubitemid 38585911)
17. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
18. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008; 112: 1876-1885.
19. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009; 114: 1958-1967.
20. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S et al. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 2011; 117: 3353-3362.
21. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913-924. (Pubitemid 47055386)